<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131120">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01906177</url>
  </required_header>
  <id_info>
    <org_study_id>GK5</org_study_id>
    <nct_id>NCT01906177</nct_id>
  </id_info>
  <brief_title>SE Asia Vanguard PS Multi-center Study</brief_title>
  <official_title>A Prospective Munti-center Study on VANGUARDâ„¢ PS Total Knee Replacement System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomet, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biomet, Inc.</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <authority>India: Institutional Review Board</authority>
    <authority>Korea: Institutional Review Board</authority>
    <authority>Malaysia: Institutional Review Board</authority>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this pilot clinical study include:

        -  Evaluate clinical outcomes and quality of life on patients who received Vanguard PS
           Total Knee in SE Asian population

        -  Evaluate safety of Vanguard PS Total Knee in SE Asian population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single cohort, multi-center study of Vanguard PS system and
      will be conducted in China, Korea, Malaysia, Thailand and India at 6 institutions. The study
      will be conducted over a period of 10 years. Patients will be followed at immediate post-op,
      6 weeks, 6 months and 1 year, 3 years in the clinic, and at 5 years, 7 years and 10 years
      via clinic or telephone.

      Total of 6 sites of 5 countries (1 China, 1 India, 2 Korea, 1 Malaysia, and 1 Thailand) will
      be involved in this study. 50 cases on each sites and total of 300 subjects will be enrolled
      in the study.

      Primary end-point will be KSS at 1 year post op and secondary end-points are Survivorship of
      the product, KSS, EQ5D, High-Flexion Knee Score, Radiographic Assessment, and any kind of
      complication including lost to follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>American Knee Society Score</measure>
    <time_frame>1 year Post Op</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survivorship - number of patients with implants</measure>
    <time_frame>10 years post op</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>10 year post op</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic Assessment - subsidence, migration, and radiolucencies</measure>
    <time_frame>10 year Post Op</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications - any AEs to patients</measure>
    <time_frame>10 year Post Op</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Traumatic Arthritis</condition>
  <condition>Correction of Varus, Valgus</condition>
  <condition>Posttraumatic Deformity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Total 300 cases

        each site of 6 sites delegated to enroll 50 cases each
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis,
             traumatic arthritis, where one or more compartments are involved.

          -  Correction of varus, valgus, or posttraumatic deformity.

          -  Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous
             joint replacement procedure

          -  Need to obtain pain relief and improve function

          -  Ability and willingness of the patient to follow instructions, including control of
             weight and activity level

          -  A good nutritional state of the patient, and

          -  The patient must have reached full skeletal maturity (at least 18 years old).

        Exclusion Criteria:

          -  infection

          -  sepsis

          -  osteomyelitis

          -  Uncooperative patient or patient with neurologic disorders who are incapable of
             following directions

          -  Osteoporosis

          -  Metabolic disorders which may impair bone formation

          -  Osteomalacia

          -  Distant foci of infections which may spread to the implant site

          -  Rapid joint destruction, marked bone loss or bone resorption apparent on
             roentgenogram

          -  Vascular insufficiency, muscular atrophy, neuromuscular disease

          -  Incomplete or deficient soft tissue surrounding the knee
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Joon Choi, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangneung Asan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Keun Seon, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew S Yoon</last_name>
    <phone>1-574-372-6697</phone>
    <phone_ext>6697</phone_ext>
    <email>andrew.yoon@biomet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>China PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Ying Chen</last_name>
      <phone>+86 139 0107 8832</phone>
      <email>chenjiying301@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ji Ying Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S R Mehta Hospital</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nilen Shah</last_name>
      <email>drnilen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nilen Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Gangneung-Si</city>
        <state>Gangwon-Do</state>
        <zip>210-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Joon Choi</last_name>
      <phone>+82-33-610-3241</phone>
      <email>cwsbest@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Young Joon Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeonnam</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Keun Seon</last_name>
      <phone>+82-61-379-7676</phone>
      <email>seonbell@yahoo.co.kr</email>
    </contact>
    <investigator>
      <last_name>Jong Keun Seon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faris Kamaruddin</last_name>
      <phone>+60 (012) 883-2178</phone>
      <email>drfariskamaruddin@yahoo.com.sg</email>
    </contact>
    <investigator>
      <last_name>Faris Kamaruddin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn Hospital</name>
      <address>
        <city>Pathumwan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aree Tanavalee</last_name>
      <phone>+66 (02) 256-4230</phone>
      <email>areetang@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Aree Tanavalee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
